Close Menu

NEW YORK – Qiagen said on Thursday that its first quarter revenues and earnings per share are expected to be significantly higher than previously issued guidance, primarily due to sales of products used in COVID-19 testing.

For the three months ended March 31, 2020, Qiagen reported preliminary revenue growth of 9 percent at constant exchange rates, compared to a prior outlook, issued on Feb. 4, of approximately 2 percent to 3 percent growth.

Sales reflected "very significant" demand for products used in COVID-19 testing against weaker customer demand in other product areas.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

An Associated Press report says China refrained from releasing the SARS-CoV-2 genome for more than a week in January, frustrating the World Health Organization.

The Lancet and the New England Journal of Medicine have issued expressions of concern regarding the data used in two COVID-19 papers, the New York Times reports. 

Researchers have sequenced the genome of the mayfly, garnering insight into how insects evolved wings, Science reports.

In Genome Research this week: gene expression in primate brain regions, inversions and breakpoint inverted repeats in the human genome, and more.

Sponsored by

This webinar will discuss the current status of COVID-19 testing, treatment and other aspects of the current pandemic as they relate to getting this outbreak under control.  

Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.